RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

OPENING SOON

Study Sponsored by Reunion Neuroscience

A Phase 2, randomized, double-blind, parallel-group, dose-controlled study to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson’s Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.

Learn More

To learn about other open trials click the button below:

View Open Clinical Trials